Point: Antenatal corticosteroid treatment in the late preterm period—Are the benefits worth the potential risks?
Autor: |
Kajantie, Eero |
Předmět: |
|
Zdroj: |
Paediatric & Perinatal Epidemiology; Jan2023, Vol. 37 Issue 1, p12-14, 3p |
Abstrakt: |
Antenatal corticosteroid treatment (ACT) is one of the success stories in improving the outcome of babies born preterm. In variance with most other guidelines, ACT not recommended when there are clinical signs of maternal chorioamnionitis |
ht 1 I Note i : With some difference in detail, all these guidelines recommend antenatal corticosteroid treatment at least up to 34 weeks. Point: Antenatal corticosteroid treatment in the late preterm period - Are the benefits worth the potential risks?. [Extracted from the article]
Databáze: |
Complementary Index |
Externí odkaz: |
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|